Clinical Trial Update: 3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MSDC-0160 on brain glucose utilization, cognition, and safety in Alzheimer's disease completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• MSDC-0160

Snippet

Sponsor: Metabolic Solutions Development Company | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2014-11-05